Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (Q26747806)

Pharmacology & Therapeutics

Europe PubMed Central

title

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (English)

0 references

0 references

Caroline Wigerup

1

0 references

Sven Påhlman

series ordinal

2

0 references

Daniel Bexell

series ordinal

3

0 references

language of work or name

English

0 references

publication date

August 2016

0 references

published in

0 references

volume

164

0 references

page(s)

152-69

0 references

cites work

Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

High levels of HIF-2α highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Endogenous hypoxia markers: case not proven!

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia in cancer: significance and impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Targeting hypoxia cell signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hif-1α and Hif-2α differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factors, stem cells, and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia requires notch signaling to maintain the undifferentiated cell state

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF targets in bone remodeling and metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Passing the baton: the HIF switch

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia Attenuates the Expression of E-Cadherin via Up-Regulation of SNAIL in Ovarian Carcinoma Cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Tumor hypoxia and malignant progression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The role of hypoxia-activated prodrugs in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Involvement of chemokine receptors in breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Studies with bleomycin and misonidazole on aerated and hypoxic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia signalling in cancer and approaches to enforce tumour regression

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

An oxygen-regulated switch in the protein synthesis machinery

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Direct regulation of TWIST by HIF-1alpha promotes metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Allosteric inhibition of hypoxia inducible factor-2 with small molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Tumour predisposition in mice heterozygous for a targeted mutation in Nf1

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Targeting HIF-1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Exploiting tumour hypoxia in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The interplay between MYC and HIF in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The impact of O2 availability on human cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Targeting hypoxia in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Deconvoluting the context-dependent role for autophagy in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Immunity, inflammation and cancer: a leading role for adenosine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

bHLH-PAS proteins in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Oxygen sensing by HIF hydroxylases

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1alpha induces cell cycle arrest by functionally counteracting Myc.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Relationship of hypoxia to metastatic ability in rodent tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Digoxin, HIF-1, and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Human cancers converge at the HIF-2alpha oncogenic axis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Targeted expression of MYCN causes neuroblastoma in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1 alpha is required for solid tumor formation and embryonic vascularization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Prognostic Significance of Hypoxia-Inducible Factor Expression in Renal Cell Carcinoma: A PRISMA-compliant Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Human cancer growth and therapy in immunodeficient mouse models

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

EO9 (Apaziquone): from the clinic to the laboratory and back again

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Development of HIF-1 inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Understanding the Warburg effect: the metabolic requirements of cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Release of dopamine and norepinephrine by hypoxia from PC-12 cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

MicroRNA regulation of DNA repair gene expression in hypoxic stress

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Collagen prolyl hydroxylases are essential for breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-Inducible Factor-1 Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Pseudohypoxic pathways in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Molecular pathways: hypoxia response in immune cells fighting or promoting cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Increased accumulation of hypoxia-inducible factor-1α with reduced transcriptional activity mediates the antitumor effect of triptolide

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The Warburg effect is genetically determined in inherited pheochromocytomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

HIF2A and IGF2 expression correlates in human neuroblastoma cells and normal immature sympathetic neuroblasts

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia-Inducible Factors (HIFs) and Phosphorylation: Impact on Stability, Localization, and Transactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

Hypoxia inducible factor-2alpha in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.009

7 January 2021

10.1016/J.PHARMTHERA.2016.04.009

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

481422

481422

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference